Radiopharmaceuticals for Cancer Diagnosis
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".
Deadline for manuscript submissions: closed (28 June 2018) | Viewed by 21926
Special Issue Editors
Interests: nuclear-based molecular imaging techniques including PET, SPECT, and PET-MRI; image quantification; immunological-based imaging agents for diagnosis of infection and cancer; radiopharmaceuticals for cancer diagnosis and therapy; radiomics
Special Issues, Collections and Topics in MDPI journals
Interests: radiotracers; drug discovery; drug development; biomarkers; end point; therapeutic effect; drug efficacy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue, “Radiopharmaceuticals for Cancer Diagnosis”, will provide a timely update on radiopharmaceuticals for diagnosing and characterizing various cancers using positron emission tomography (PET) or single photon emission computed tomography (SPECT). These radiopharmaceuticals are molecular imaging tools that are critical to the diagnosis and staging of cancers, as well as in selecting patients for various therapies and monitoring their outcomes.
Significant advances in radiochemistry and radiopharmaceutical production have allowed for wider adoption of nuclear-based molecular imaging techniques, such as PET and SPECT. Recently, new cancer-targeting diagnostic and “theranostic” radiopharmaceuticals have become commercially available. There are several others in the regulatory approval pipeline.
This Special Issue will specifically explore novel radiopharmaceuticals for the diagnosis or characterization of various cancers, new applications for well-characterized radiopharmaceuticals, new radiochemistry methodologies, and novel strategies in quantitative molecular imaging of radiopharmaceuticals, as applied to cancer.
Submissions contributing to the understanding of the use of radiopharmaceuticals in the diagnosis or characterization of cancer, through basic science, pre-clinical, and clinical studies are cordially invited.
Both original manuscripts and reviews will be considered.
Prof. Dr. Benjamin Franc
Dr. Krishan Kumar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Cancer imaging
- Radiochemistry
- Radiopharmaceuticals
- Positron emission tomography (PET)
- Single photon emission computed tomography (SPECT)
- Theranostics
- Immuno-PET
- Antibody imaging
